AbCellera's Lead Candidate ABCL635 Advances to Phase 2 Clinical Trial for Menopausal Vasomotor Symptoms
ABCL has more than doubled off its 52-week low of $1.891.
Summary
AbCellera Biologics announced that its lead drug candidate, ABCL635, has advanced into Phase 2 clinical trials for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, following positive Phase 1 safety and pharmacodynamic data.
Key Events · Product Development and Regulatory · ABCL
-
ABCL635 Enters Phase 2 Clinical Trial
AbCellera announced that the first patients have been dosed in the Phase 2 portion of its Phase 1/2 clinical trial for ABCL635.
-
Targeting Menopausal Vasomotor Symptoms
ABCL635 is a potential first-in-class non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause.
-
Positive Phase 1 Data Supported Advancement
The transition to Phase 2 follows an interim review of encouraging safety, tolerability, and pharmacodynamic data from the Phase 1 portion of the study.
-
Top-Line Results Expected Q3 2026
The company anticipates releasing top-line clinical results for both Phase 1 and Phase 2 portions of the trial in the third quarter of 2026.
Analysis · ABCL · Life Sciences
The advancement of ABCL635 into Phase 2 clinical trials is a significant milestone for AbCellera, a clinical-stage biotechnology company. This progression, based on encouraging Phase 1 safety and pharmacodynamic data, de-risks the program and validates the company's internal pipeline development strategy. ABCL635 is positioned as a potential first-in-class non-hormonal antibody for a large market with unmet needs, aiming to offer advantages over existing small molecule treatments. Investors should closely monitor the anticipated top-line clinical results in Q3 2026, as these will be crucial for further evaluating the drug's efficacy and safety profile.
How filings like this one have moved
In the 30 days to Sep 19, 2026, 29% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABCL was trading at $4.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $1.89 to $6.52. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.